SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:liu-45525"
 

Search: onr:"swepub:oai:DiVA.org:liu-45525" > Risk factors for re...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005078naa a2200553 4500
001oai:DiVA.org:liu-45525
003SwePub
008091011s2005 | |||||||||||000 ||eng|
009oai:DiVA.org:uu-104221
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-455252 URI
0247 a https://doi.org/10.1097/01.TP.0000147338.34323.122 DOI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1042212 URI
040 a (SwePub)liud (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Fellström, Bengt,d 1942-u Uppsala universitet,Institutionen för medicinska vetenskaper,The Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators,Fellström, B., University Hospital, Uppsala, Sweden, Department of Medical Science, Renal Unit, University Hospital, Uppsala, Sweden4 aut0 (Swepub:uu)bengfell
2451 0a Risk factors for reaching renal endpoints in the Assessment of Lescol in Renal Transplantation (ALERT) trial
264 1c 2005
338 a print2 rdacarrier
520 a Background. The aim of the study was to identity risk factors for long-term renal transplant function and development of chronic allograft nephropathy (CAN) in renal transplant recipients included in the Assessment of Lescol in Renal Transplantation (ALERT) trial. Methods. The ALERT trial was a randomized, double-blind, placebo-controlled study of the effect of fluvastatin, 40 and 80 mg/day, in renal transplant recipients who were randomized to receive fluvastatin (Lescol) (n=1,050) or placebo (n=1,052) over 5 to 6 years of follow-up. Renal endpoints including graft loss or doubling of serum creatinine or death were analyzed by univariate and multivariate regression analysis in the placebo group. Results. There were 137 graft losses (13.5%) in the placebo group, mainly caused by CAN (82%). Univariate risk factors for graft loss or doubling of serum creatinine were as follows: serum creatinine, proteinuria, hypertension, pulse pressure, time since transplantation, donor age, human leukocyte antigen-DR mismatches, treatment for rejection, low high-density lipoprotein cholesterol, and smoking. Multivariate analysis revealed independent risk factors for graft loss as follows: serum creatinine (relative risk [RR], 3.12 per 100-µM increase), proteinuria (RR, 1.64 per 1-g/24 hr increase), and pulse pressure (RR, 1.12 per 10 mm Hg), whereas age was a protective factor. With patient death in the composite endpoint, diabetes mellitus, smoking, age, and number of transplantations were also risk factors. Conclusions. Independent risk factors for graft loss or doubling of serum creatinine or patient death are mainly related to renal transplant function, proteinuria, and blood pressure, which emphasizes the importance of renoprotective treatment regimens in this population.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Urologi och njurmedicin0 (SwePub)302142 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Urology and Nephrology0 (SwePub)302142 hsv//eng
653 a Chronic rejection
653 a Graft loss
653 a Renal transplantation
653 a Risk factors
653 a MEDICINE
653 a MEDICIN
653 a Kidney diseases
653 a Medicin
7001 a Holdaas, H.u Rikshospitalet, Oslo, Norway,the Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators,Univ. Klin. Charité, Berlin, Germany4 aut
7001 a Jardine, A.G.u University of Glasgow, Glasgow, United Kingdom,the Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators4 aut
7001 a Nyberg, G.u Sahlgrenska University Hospital, Göteborg, Sweden,the Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators4 aut
7001 a Gronhagen-Riska, C.u Grönhagen-Riska, C., University Hospital, Helsinki, Finland4 aut
7001 a Madsen, S.u Skejby Hospital, Aarhus, Denmark4 aut
7001 a Neumayer, H.-H.u Univ. Klin. Charité, Berlin, Germany4 aut
7001 a Cole, E.u Toronto General Hospital, Toronto, Ont., Canada4 aut
7001 a Maes, B.u University Hospital, Leuven, Belgium4 aut
7001 a Ambuhl, P.u Ambühl, P., University Hospital, Zürich, Switzerland4 aut
7001 a Olsson, Andersu Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Internmedicin,Endokrin- och magtarmmedicinska kliniken US4 aut0 (Swepub:liu)andol21
7001 a Staffler, B.u Novartis, Basel, Switzerland4 aut
7001 a Pedersen, T.R.u Preventive Medicine Clinic, Ullevaal University Hospital, Oslo, Norway4 aut
7102 a Uppsala universitetb Institutionen för medicinska vetenskaper4 org
7730 t Transplantationg 79:2, s. 205-212q 79:2<205-212x 0041-1337x 1534-6080
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-45525
8564 8u https://doi.org/10.1097/01.TP.0000147338.34323.12
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-104221

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view